drugset / Trial / NCT07032662
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a Phase 2b study to evaluate the efficacy and safety of Imeroprubart in adults with CIDP.
Timeline
- Start
- 2025-03-18
- Primary completion
- 2028-08
- Completion
- 2030-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imeroprubart | Monoclonal antibody | — | Subcutaneous |